Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME study: pemafibrate vs eicosapentaenoic acid for vascular function in hypertriglyceridemia with coronary artery disease
jRCTs061200010Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in hypertriglyceridemia, coronary arteriosclerosis and dyslipidemia comparing Pemafibrate with Eicosapentaenoic acid (2 arms). Primary endpoint: Change in lnRHI at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
pemafibrateeicosapentaenoic acid
03
Conditions
hypertriglyceridemiacoronary arteriosclerosisdyslipidemia
Beyond the preview
Go deeper on jRCTs061200010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061200010.